Estrogen receptor positivity in luminal-type breast cancers helps pathologists to distinguish those lesions from other malignancies such as gastrointestinal tumors, but triple-negative breast cancers, which, invariably, are hormone-receptor negative, frequently need additional immunohistochemical workup. This evidence concerns the gene NR4A1 and breast carcinoma.